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Aspirin therapy in patients with acute respiratory
distress syndrome (ARDS) is associated with
reduced intensive care unit mortality: a
prospective analysis
Andrew J Boyle1,2*, Stefania Di Gangi3, Umar I Hamid1, Linda-Jayne Mottram2, Lia McNamee2, Griania White2,
LJ Mark Cross1,2, James J McNamee2, Cecilia M O’Kane1 and Daniel F McAuley1,2
Abstract
Introduction: Acute respiratory distress syndrome (ARDS) is a common clinical syndrome with high mortality and
long-term morbidity. To date there is no effective pharmacological therapy. Aspirin therapy has recently been
shown to reduce the risk of developing ARDS, but the effect of aspirin on established ARDS is unknown.
Methods: In a single large regional medical and surgical ICU between December 2010 and July 2012, all patients
with ARDS were prospectively identified and demographic, clinical, and laboratory variables were recorded
retrospectively. Aspirin usage, both pre-hospital and during intensive care unit (ICU) stay, was included. The primary
outcome was ICU mortality. We used univariate and multivariate logistic regression analyses to assess the impact of
these variables on ICU mortality.
Results: In total, 202 patients with ARDS were included; 56 (28%) of these received aspirin either pre-hospital,
in the ICU, or both. Using multivariate logistic regression analysis, aspirin therapy, given either before or during
hospital stay, was associated with a reduction in ICU mortality (odds ratio (OR) 0.38 (0.15 to 0.96) P = 0.04).
Additional factors that predicted ICU mortality for patients with ARDS were vasopressor use (OR 2.09 (1.05 to 4.18)
P = 0.04) and APACHE II score (OR 1.07 (1.02 to 1.13) P = 0.01). There was no effect upon ICU length of stay or
hospital mortality.
Conclusion: Aspirin therapy was associated with a reduced risk of ICU mortality. These data are the first to
demonstrate a potential protective role for aspirin in patients with ARDS. Clinical trials to evaluate the role of aspirin
as a pharmacological intervention for ARDS are needed.
Introduction
Acute respiratory distress syndrome (ARDS) is a com-
mon devastating clinical syndrome characterised by
life-threatening hypoxaemic respiratory failure often
requiring mechanical ventilation and frequently leading to
multiple organ failure. ARDS is a major cause of morbidity
and mortality within the ICU, and causes long-term
reduction in quality of life for survivors [1-3].
ARDS is an inflammatory condition characterised by
neutrophil-mediated [4,5] and macrophage-mediated [6]
injury. This uncontrolled local inflammatory response
causes alveolar epithelial and capillary endothelial barrier
damage, increasing its permeability. This allows the accu-
mulation of an inflammatory infiltrate, and proteinaceous
fluid within the alveolar space (non-cardiogenic pulmonary
oedema) that contributes to profound hypoxaemia. The
accompanying widespread activation of the coagulation
cascade leads to microvascular thrombosis and fibroproli-
feration [7]. Currently there are few effective interventions
for ARDS [8,9], and these primarily involve limiting
ventilator-induced lung injury with low tidal volume
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ventilation [10], prone positioning [11], with emerging
data for neuromuscular blockade [12] and extra-corporeal
therapies [13,14].
Platelets have an increasingly recognised role in the
inflammatory response leading to the development of
ARDS. Platelet activation mediates neutrophil-recruitment
to the lung in an acid-induced murine model of lung injury,
an effect that is inhibited by pre-treatment with aspirin
[15]. Platelet depletion in two mouse models of ARDS
reduced the severity of lung injury and increased survival,
an effect that was reproduced by pre-treatment with aspirin
[16]. In addition, delayed neutrophil apoptosis is a feature
of ARDS that aspirin can ameliorate to promote resolution
of persisting inflammation [17].
Most, but not all [18,19] observational data suggest
that aspirin use prior to ICU admission (without ARDS
at the point of admission) may reduce the subsequent
development of ARDS [20-22]. Finally, in a cohort of
patients admitted with community-acquired pneumonia,
those patients being treated with anti-platelet drugs (the
majority of whom received aspirin) had a significantly
lower rate of critical care admission [23].
These data suggest that aspirin may prevent ARDS,
however, it is unknown if aspirin exposure alters outcome
in patients with established ARDS. Aspirin exposure in
patients with systemic inflammatory response syndrome
(SIRS), severe sepsis or septic shock is associated with
reduced mortality [24,25], but there are no data in patients
with ARDS. We hypothesised that aspirin treatment,
either prior to, or during ICU admission, would reduce
mortality in patients with ARDS. To assess this, we
prospectively identified patients with ARDS to determine
the effect of aspirin exposure on mortality within ICU.
Methods
We conducted an audit of ARDS management between
December 2010 and July 2012. This was a convenience
sample and a formal sample size calculation was not
performed. The Belfast Health and Social Care Trust
determined this project as an audit, because patient
management was not altered, only routinely collected
data were used and the data were fully anonymised,
and as a result research ethics committee approval
was not required. The requirement for patient consent
was therefore waived.
Patient population
All adult patients (>16 years-old) requiring invasive
mechanical ventilation admitted to the 17-bed mixed
medical and surgical Regional Intensive Care Unit in the
Royal Victoria Hospital, Belfast, were prospectively
screened daily as part of ongoing clinical trials of ARDS
(53 of the patients included in this analysis were rando-
mised to a clinical trial). Patients who met the North
American-European consensus conference definition of
acute lung injury [26] (a term now replaced by ARDS
[27], and to which we refer throughout) were identified
prospectively and included. There were no exclusion
criteria. Determination of ARDS was made by trained
research coordinators who are involved in the screening
of patients with ARDS for recruitment into clinical trials
ongoing within the ICU, and where there was any uncer-
tainty the attending physician confirmed the diagnosis of
ARDS. Patients were screened daily from admission for
the diagnosis of ARDS, and were included in this cohort
once they met the criteria for diagnosis.
Data collection
Baseline demographics recorded were age, gender,
and acute physiology and chronic health evaluation
(APACHE) II score at admission to ICU. We recorded a
medical history of alcohol dependency, smoking, liver
cirrhosis, ischaemic heart disease, congestive heart failure,
chronic obstructive airways disease, cerebrovascular
disease and diabetes mellitus. We also recorded whether
patients received a statin prior to admission. Medication
history was obtained through chart review and medication
reconciliation completed by the ICU pharmacist, who
contacted the community general practitioner to complete
these data if necessary. The ratio of partial pressure of
arterial oxygen (PaO2) to fraction of inspired oxygen
(FiO2), sequential organ failure assessment (SOFA) score
on the day of ARDS diagnosis and the aetiology of ARDS
was recorded. Aspirin usage both pre-admission and
during ICU stay was included. Patients were deemed to
have been treated with aspirin if it was part of their pre-
hospital medication, or if given whilst in ICU (or both).
All records were reviewed by a qualified physician.
Primary and secondary outcomes
The primary outcome was ICU mortality. Secondary
outcomes included duration of ICU stay and hospital
mortality.
Statistical methods
We compared patients with ARDS who received aspirin
(aspirin ever) with those who did not (no aspirin). Baseline
characteristics and outcome variables were compared
using standard tests for continuous and binary variables.
We reported results of the Kruskal-Wallis or chi
squared test, as appropriate, when we compared three
or more groups.
Data are presented as mean (SD), median (IQR) and
number (%) as appropriate. The number of non-missing
observations is shown when different from the overall
population. The distributions of all variables were tested
for normality. The independent sample Student’s t-test was
used for continuous variables with a normal distribution.
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Otherwise, the Wilcoxon‐Mann‐Whitney was used when
normality was violated. The chi squared test or Fisher’s
exact two-sided test, as appropriate, were used for binary
variables. A P-value ≤0.05 was considered statistically
significant.
Univariate and multivariate logistic regression models
were performed to identify the association between baseline
characteristics and the primary outcome. We used multi-
variate logistic regressions to calculate (adjusted) odds ra-
tios (OR) and 95% confidence intervals (CI) for the
association between aspirin use and outcomes. Adjust-
ments for any potential confounding effects were made for
clinically relevant variables and for those that showed a sta-
tistically significant difference between the groups at
baseline.
We further examined the adjusted effect of aspirin use
on the primary and secondary outcomes with multivari-
ate Cox proportional hazards regression models. The
dates of admission to ICU or hospital, respectively, were
the starting points of the survival analyses and the dates of
discharge from ICU, or hospital, were the endpoints.
Multivariate models were constructed using automatic
stepwise selection estimation with likelihood ratio
testing (P-value ≤0.20) specified as the test of signifi-
cance to include or exclude variables. Aspirin expos-
ure (as the variable of interest), and history of
coronary artery disease (as a significant, potential
confounder) were locked into the model and not sub-
ject to the selection criteria. In a secondary analysis,
combined aspirin and statin exposure, and history of
coronary artery disease, were locked into the model.
APACHE and SOFA as severity of illness scores were
not both included in the multivariate model because
of the problem of co-linearity in that the scores are
correlated, because the severity of illness variables by
which they are calculated are broadly the same or
correlated. The Kaplan-Meier curve was used to plot
ICU survival between patient groups with the log
rank test used to determine differences among these
groups. STATA SE version 11.0 (StataCorp LP, TX, USA)
was used for all analyses. Graphs were constructed using
GraphPad Prism (v 6.0).
Results
Two hundred and two patients with ARDS were
included; 56 (28%) received aspirin either pre-hospital
(n = 31, 55% of total aspirin), in ICU (n = 7, 13%) or
both pre-hospital and in ICU (n = 18, 32%). The dose of
aspirin received ranged from 75 mg daily (n = 53, 95%) to
300 mg daily. Patient demographics are summarised in
Table 1. Patients treated with aspirin were likely to be
older (71 versus 56; P <0.001) and have greater co-
morbidities. The use of statin therapy was higher in the
aspirin group (37 versus 24; P = <0.001).
ICU mortality
The primary analysis involved those who had taken
aspirin ever compared with those never exposed. In
univariate analysis four variables were associated with
ICU mortality; patient age, APACHE II score, SOFA
score and vasopressor use (Table 2). Although aspirin
exposure was not associated with an impact upon mortality
in the univariate analysis (Table 2), in a multiple logistic
regression analysis, treatment with aspirin was associated
with a significantly lower ICU mortality compared with
patients who had no aspirin exposure (OR 0.38 (0.15 to
0.96); P = 0.04). The use of vasopressors during admission
(OR 2.09 (1.05 to 4.18); P = 0.04) and APACHE II score at
admission (OR 1.07 (1.02 to 1.13); P = 0.01) was associated
with an increased risk of death (Table 3).
In analysis of the combined effect of aspirin and statin
therapy, patients exposed to both drugs had no ICU
survival advantage (OR 0.68 (0.26, 1.80); P = 0.44) (Table 4).
To determine the effect of timing of treatment we
analysed the different subgroups of patients treated
with aspirin (aspirin pre-ICU, aspirin pre-ICU and in
ICU, aspirin in ICU only) and those never treated
with aspirin. Although there was increased survival in
patients started on aspirin within ICU, there was no
significant difference in survival amongst the groups
(log rank test, P = 0.48) (Figure 1).
Length of ICU stay
Aspirin treatment was not associated with a significant
impact upon ICU length of stay (hazard ratio (HR) 0.64
(0.33 to 1.25), P = 0.19), whilst APACHE II score corre-
lated with a longer ICU admission (HR 1.07 (1.03 to 1.12),
P = 0.001) P = 0.001).
Hospital mortality
The association of aspirin did not extend to overall
hospital mortality (OR 0.91 (0.46 to 1.78); P = 0.78).
APACHE II score positively correlated with hospital
mortality (OR 1.09 (1.04 to 1.14); P <0.001).
Discussion
In this prospectively identified audit of ARDS management,
we found aspirin therapy to be associated with a reduced
risk of ICU mortality from ARDS. Using multivariate
analysis in patients with ARDS, we found aspirin was
an independent factor associated with a reduction in
risk of death within ICU, whilst the use of vasopressors
and APACHE II score at ICU admission correlated with
increased risk of ICU death. This is the first report to find
aspirin therapy is associated with reduced ICU mortality
in patients with established ARDS.
There are several processes that aspirin may modulate
to provide a beneficial effect in ARDS. Aspirin has
significant anti-platelet properties through the inhibition
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of cyclo-oxygenase enzymes that prevent thromboxane
A2 production, therefore suppressing platelet aggregation;
an effect that can last up to 10 days post administration
[28]. Platelets aggregate at sites of lung injury and act as
signalling molecules to propagate an immune response,
facilitating the recruitment of neutrophils to the injured
alveolus [15]. Our findings in this cohort could be
explained by the anti-platelet effect of aspirin, which
prevents neutrophil recruitment and infiltration of the
alveolar space. This hypothesis is supported by animal
models of ARDS that show reductions in neutrophil
migration to the alveolar space in mice treated with
aspirin [29], suggesting that aspirin therapy is effective in
reducing the severity of ARDS by modulating platelet-
neutrophil interactions.
Neutrophil recruitment to sites of lung injury may also
be modulated through aspirin-triggered anti-inflammatory
mediators. Aspirin acetylates cyclo-oxygenase-2, which
results in the production of aspirin-triggered Resolvin D1
(AT-RvD1), an anti-inflammatory lipid mediator that
can reduce neutrophil transendothelial migration in a
peritonitis model [30]. In a murine model of ARDS,
Table 1 Baseline characteristics of patients with acute lung injury
Overall Aspirin ever No aspirin P-value
(n = 202) (n = 56, 28%) (n = 146, 72%)
Age
Median 61 71 56 <0.001*
IQR 46 to 71 60 to 77 41 to 68
Male
Number (%) 129 (64) 40 (71) 89 (61) 0.17
APACHE II score
Median 19 21 18 0.10
IQR 14 to 24 17 to 24 13 to 24
SOFA
Median 8 8 8 0.99
IQR 6 to 11 7 to 11 6 to 11
PaO2/FiO2 ratio
Median 22.9 21.1 23.5 0.08
IQR 17 to 30 16 to 27 18 to 31
Vasopressor use
Number (%) 95 (47) 30 (54) 65 (45) 0.25
Sepsis
Number (%) 111 (55) 29 (52) 82 (56) 0.58
Coronary artery disease
N (%) 33 (16) 22 (39) 11 (8) <0.001
Cerebrovascular disease
Number (%) 12 (6) 9 (16) 3 (2) 0.001*
COPD
Number (%) 29 (14) 13 (23) 16 (11) 0.02*
Diabetes mellitus
Number (%) 30 (15) 18 (32) 12 (8) <0.001*
Smoker
Number (%) 99 (49) 34 (61) 65 (45) 0.04*
Alcohol abuse/liver cirrhosis
Number (%) 58 (29) 9 (16) 49 (34) 0.01*
Pre-admission statin
Number (%) 61 (30) 37 (66) 24 (16) <0.001*
*Values that were deemed significant. APACHE II, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; PaO2, arterial oxygen
partial pressure; FiO2, fraction of inspired oxygen; COPD, chronic obstructive pulmonary disease.
Boyle et al. Critical Care  (2015) 19:109 Page 4 of 8
AT-RVD1 treatment was shown to reduce neutrophil
and macrophage recruitment to the site of lung
injury, in addition to restoring the capillary-endothelial
alveolar-epithelial barrier function. This suggests that
aspirin therapy can decrease severity and augment
resolution of ARDS [31].
Delayed neutrophil apoptosis is a prominent feature of
ARDS [32], allowing inflammatory cells to remain within
the alveolar space, prolonging the period of lung injury and
hypoxia. Aspirin has previously been shown to preserve
neutrophil apoptosis [17] and in the setting of ARDS,
experimental evidence suggests that aspirin-triggered
production of the anti-inflammatory lipid mediator 15-epi-
lipoxin A4 restores neutrophil apoptosis and enhances the
resolution of alveolar inflammation [33]. The effect of
aspirin may be dose-dependent [34] and although our data
support the role of low-dose therapy, we require future
clinical trials to investigate the most appropriate dose for
aspirin in ARDS.
Prior observational studies involving aspirin and ARDS
suggest an association between aspirin exposure and
prevention of ARDS in at-risk groups [20-22], but as yet
there is no evidence about aspirin use as a therapy for
ARDS. In sepsis, the most common precipitant of ARDS,
observational studies have shown reduced mortality
when aspirin is administered during the course of illness
[24,25]. In addition, there are clinical implications from
our audit. In our cohort, 63% of pre-hospital aspirin
users had their anti-platelet therapy discontinued at
ICU admission, often without documented justification.
Previous observational studies have shown reduced ICU
mortality in patients exposed to aspirin prior to ICU
admission [35], and the addition of our data suggests that
consideration should be given to continuing aspirin at
ICU admission provided no contraindications exist [36].
Pre-admission statin prescription was higher in the aspirin
cohort. The combined effect of aspirin and statin treatment
has previously been associated with a reduced incidence of
ARDS [19], however in our cohort there was no association
with an ICU survival advantage, suggesting that there
is limited therapeutic benefit of combined treatment
in ARDS. This finding adds to recent clinical trials
suggesting that there is a limited role for statin therapy in
ARDS [37,38].
Of the different subgroups of patients treated, those
who were prescribed aspirin within ICU showed the great-
est survival benefit although this did not reach statistical
significance, which may have been related to the small
patient number. We are cautious in our interpretation of
this, and believe that further clinical trials are required to
assess the benefit of aspirin as a treatment for ARDS.
Our patients were prospectively identified as part of
ongoing screening for recruitment to clinical trials within
our ICU, and we believe this identification process to be a
strength that supports the reliability of our findings.
We found APACHE II score and vasopressor use to be
Table 4 Multivariate model for analysis of ICU mortality
including patients with combined aspirin and statin
exposure
Predictor Odds ratio (95% CI) P-value
Aspirin and statin exposure 0.68 (0.26, 1.80) 0.44
Age 1.01 (0.99, 1.04) 0.21
APACHE II score 1.07 (1.02, 1.13) 0.01*
Coronary artery disease 1.01 (0.39, 2.63) 0.99
PaO2/FiO2 ratio 0.97 (0.94, 1.01) 0.15
Vasopressor use 2.06 (1.04, 4.08) 0.04*
*Values that were deemed significant. APACHE II score on admission is
presented as a continuous variable.
Table 3 Multivariate analysis of ICU mortality
Predictor Odds ratio (95% CI) P-value
Aspirin use 0.38 (0.15, 0.96) 0.04*
Age 1.02 (1.00, 1.05) 0.10
APACHE II score 1.07 (1.02, 1.13) 0.01*
Coronary artery disease 1.16 (0.43, 3.10) 0.77
PaO2/FiO2 ratio 0.97 (0.93, 1.00) 0.08
Vasopressor use 2.09 (1.05, 4.18) 0.04*
*Values that were deemed significant. APACHE II score on admission is
presented as a continuous variable. APACHE II, acute physiology and chronic
health evaluation; PaO2, arterial oxygen partial pressure; FiO2, fraction of
inspired oxygen.
Table 2 Univariate analysis of ICU mortality
Predictor Univariate analysis
Odds ratio (95% CI) P-value
Age 1.03 (1.00, 1.05)* 0.01*
Male 0.65 (0.34, 1.22) 0.18
APACHE II score 1.10 (1.05, 1.16)* <0.001*
PaO2/FiO2 ratio 0.97 (0.93, 1.00)* 0.06*
SOFA score 1.35 (1.21, 1.50)* <0.001*
Vasopressor use 2.54 (1.34, 4.81)* 0.004*
Aspirin use (ever) 0.75 (0.37, 1.53)* 0.43*
Smoking 0.82 (0.44, 1.53) 0.54
Coronary artery disease 1.20 (0.53, 2.71)* 0.67*
Diabetes mellitus 1.41 (0.61, 3.24) 0.42
Pre-admission statin 0.95 (0.46, 1.97) 0.90
COPD 0.83 (0.33, 2.07) 0.69
Cerebrovascular disease 0.88 (0.23, 3.40) 0.86
Alcohol abuse history or cirrhosis 1.30 (0.67, 2.54) 0.44
Sepsis 1.63 (0.86, 3.09) 0.13
*Values that were taken forward to multivariate analysis. APACHE II, acute
physiology and chronic health evaluation; SOFA, sequential organ failure
assessment; PaO2, arterial oxygen partial pressure; FiO2, fraction of inspired
oxygen; COPD, chronic obstructive pulmonary disease.
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associated with increased ICU mortality from ARDS, and
this finding confirms previous studies that have shown
these as independent predictors of ICU mortality [39],
supporting that this cohort is representative.
The limitations of our findings are in keeping those of
observational studies. The aspirin cohort had higher
rates of associated co-morbidity, and it could be that
aspirin usage is a surrogate for an unknown con-
founding factor. We opted to combine patients who
received aspirin pre-admission and during admission
into a single cohort because of the prolonged inhibition of
thromboxane A2 for up to 10 days [28]. However many of
our patients did not receive aspirin within ICU. In
addition, adverse events associated with the continuation
of aspirin in ICU were not consistently recorded.
Therefore, it is feasible that the efficacy and safety
profile could be different when aspirin is used specifically
as a treatment for ARDS in ICU. Although prior observa-
tional data suggest benefit in continuing aspirin in patients
with a high risk of bleeding [35], it is important that the
potential risks associated with aspirin in this patient
population are clarified in future clinical trials of
aspirin as a treatment for ARDS. These findings may
have been confounded by the so-called healthy user
effect [40], whereby the more unwell patients have
their medications, including aspirin, discontinued.
Although unable to control for this in our cohort, we
believe the finding that both APACHE II and SOFA
scores were similar between the groups suggests that
this effect has not had a significant impact upon our
findings. The use of ICU mortality as the primary
outcome measure is a potential limitation, however
we believe it reflects the outcome specifically from
ARDS, whilst the cause of hospital mortality may be
unrelated to the development of ARDS. However the
lack of an association with aspirin usage and hospital
mortality may indicate the association with aspirin
and clinical outcomes is limited and therefore further
research is required to confirm these findings. Finally,
smoking and alcohol consumption histories were
obtained from review of the medical chart. We acknow-
ledge that this is a potential limitation in the assess-
ment of these factors within our cohort and may not
fully represent the confounding effects of smoking
and alcohol [41].
At present our findings are hypothesis-generating, and
support the need for clinical trials to investigate aspirin
as a therapy for ARDS. In addition to trials investigating
aspirin as a preventative treatment for ARDS [42], our
group is currently investigating aspirin in a model of
ARDS induced by inhaled lipopolysaccharide (LPS) in
healthy volunteers (ARENA, NCT01659307) and are
planning a phase-2 study of aspirin in patients with
ARDS (STAR, NCT02326350). Both of these trials will
better inform clinicians as to the clinical potential of
aspirin as a therapy for ARDS.
Conclusion
In summary, our audit demonstrates an association
between aspirin use and reduced ICU mortality in patients
with ARDS. Early-phase clinical trials investigating the
potential for aspirin as a therapy for ARDS are needed.
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Figure 1 ICU survival in different aspirin exposure groups. Kaplan-Meier graph showing survival status for patients in the four different
subgroups of aspirin treatment. There was no significant difference in survival amongst the groups (log rank test, P = 0.48).
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Key messages
 In this audit aspirin therapy is associated
with reduced risk of ICU mortality in patients
with ARDS.
 APACHE II score and vasopressor use correlate
with ICU mortality.
 There is a need for clinical trials investigating the
role for aspirin in ARDS.
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